JAMA Network
About The Study: In this secondary analysis of a randomized clinical trial, patients who received at least one COVID-19 vaccine dose after acute coronary syndromes had similar rates of the primary composite end point and major adverse cardiovascular events (MACE) compared with unvaccinated patients. However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
